Movement Alert|Hca Healthcare Inc Rises 3.76% in Regular Trading, Q2 Revenue and Earnings Beat Expectations

Market Focus
Jul 24

On July 24, Hca Healthcare Inc rose 3.76% in regular trading, trading at $389.86/share, with turnover of $53.31 million. The stock gained after the company reported second-quarter results that significantly exceeded analyst expectations on both the top and bottom lines.

For Q2, HCA reported revenue of $20.23 billion, up from $18.61 billion a year earlier, beating the consensus estimate of approximately $19.4-19.76 billion. Adjusted EPS came in at $7.59, representing a 10.96% increase over $6.84 a year ago and surpassing the Street estimate of $7.02-7.56. Same-facility admissions grew 2.5% year-over-year, while emergency room visits increased 3.6%, indicating robust demand trends. Adjusted EBITDA reached $4.027 billion, up 4.6%. However, the company lowered its full-year profit guidance, citing approximately $400 million in pre-tax earnings impact from a shift in patient payment mix toward uninsured patients. Full-year adjusted EBITDA expectations were reduced to $15.4-16.1 billion.

Within the Health Care Facilities sector, peers rallied broadly: Tenet Healthcare up 22.67%, Surgery Partners up 6.18%, Universal Health up 5.59%, Encompass Health Corporation up 3.15%, US Physical Therapy up 2.21%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10